Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

172P - Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Simona Bruzas

Citation

Annals of Oncology (2020) 31 (suppl_4): S303-S339. 10.1016/annonc/annonc267

Authors

S. Bruzas1, S. Kümmel1, N. Harbeck2, P. Schmid3, J. Cortés4, C. Seiberling1, O. Chiari1, H. Harrach1, B. Ataseven5, M. Dyson1, E. Traut1, I. Theuerkauf6, D. Gebauer6, O. Gluz7, M. Reinisch1

Author affiliations

  • 1 Interdisciplinary Breast Unit, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 2 Breast Center, Dept. Ob&gyn And Ccclmu, University of Munich (LMU), 81377 - Munich/DE
  • 3 Centre For Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, EC1M 6BQ - London/GB
  • 4 Oncology Department, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona and Vall d´Hebron Institute of Oncology (VHIO), 8035 - Barcelona/ES
  • 5 Clinic For Gynecology And Gynecological Oncology, And Interdisciplinary Breast Unit, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 6 Institut Für Pathologie Viersen, Institut für Pathologie Viersen, 41747 - Viersen/DE
  • 7 West German Study Group And Breast Center Niederrhein, Evangelical Hospital Bethesda, 41061 - Moenchengladbach/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 172P

Background

A substantial minority of EBC pts relapse despite pCR after neoadjuvant therapy. We compared gene expression between primary tumors of pts with relapse despite pCR and: (i) primary tumors from matched controls with pCR and no relapse (interindividual analysis), or (ii) matched recurrent tumors (intraindividual analysis).

Methods

This retrospective single-center study included 14 pts (8 hormone receptor-positive, 5 HER2+, 5 triple-negative [TN]) with relapse despite pCR (8 distant, 6 locoregional) plus 41 matched controls with pCR and no relapse. To exclude undetected primary metastatic disease, time to distant relapse >12 months was required. RNA from primary and recurrent tumors was analyzed (Breast Cancer 360 panel, nCounter® platform; NanoString). Differential expression of 42 genes/signatures was evaluated as log2 fold-change (logFC) and compared by t test ± false-discovery rate (FDR) adjustment.

Results

Analysis was successful in 68/69 samples. In interindividual analyses of primary tumors, major histocompatibility complex class II expression was lower vs. controls in pts with any relapse (logFC -0.819; P = 0.030) or distant relapse (logFC -1.151; P = 0.013). Primaries with later distant relapse also had lower interferon-γ signaling (logFC -0.759; P = 0.050) and greater homologous recombination deficiency (logFC 0.649; P = 0.026) vs. controls. In subgroup analyses, relapse was associated with higher mammary stemness (logFC 1.716; P = 0.026), progesterone receptor (logFC 1.027; P = 0.027) and endothelial cells (logFC 0.827; P = 0.033) in TN pts, and higher proliferation score (logFC 0.721, P = 0.023) in HER2+ pts. Intraindividual analysis showed androgen receptor upregulation (logFC 1.264, P = 0.046) and downregulation of TIGIT (logFC -1.037, P = 0.040) and estrogen receptor signaling (logFC -0.595, P = 0.022) in recurrent tumors vs. primaries. FDR-adjusted P-values were not significant.

Conclusions

These correlations between gene expression and relapse despite pCR warrant further investigation to identify pts who remain at high risk in this setting, e.g. in future immunotherapy, poly(ADP-ribose) polymerase inhibitor or targeted HER2-enriched trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Kümmel: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Genomic Health; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Celgene; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Somatex; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: PFM Medical; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sonoscape; Leadership role, Shareholder/Stockholder/Stock options, Partial non-profit ownership: WSG (Westdeutsche Studiengruppe); Leadership role: AGO (Arbeitsgemeinschaft Gynäkologische Onkologie). N. Harbeck: Honoraria (institution): only research grants; Advisory/Consultancy: Agendia; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Daiichi Sankyo; Advisory/Consultancy: Genomic Health; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy: Odonate; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Sandoz/Hexal; Advisory/Consultancy: Seattle Genetics; Speaker Bureau/Expert testimony: Amgen; Speaker Bureau/Expert testimony: Nanostring; Leadership role: German AGO Breast Committee; Research grant/Funding (institution): several phase II-III trials; Shareholder/Stockholder/Stock options: Co-Director West German Study Group; Full/Part-time employment: LMU Munich; Spouse/Financial dependant: West German Study Group. P. Schmid: Advisory/Consultancy: Pfizer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution), Spouse/Financial dependant: Roche; Advisory/Consultancy: Merck; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Celgene; Advisory/Consultancy: Puma; Research grant/Funding (institution), Spouse/Financial dependant: Genentech; Research grant/Funding (institution): Oncogenex. J. Cortés: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Celgene; Advisory/Consultancy: Cellestia; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biothera Pharmaceutical; Advisory/Consultancy: Merus; Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Erytech; Advisory/Consultancy: Athenex; Advisory/Consultancy: Polyphor; Honoraria (self), Advisory/Consultancy: Lilly; Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme; Advisory/Consultancy: GSK; Advisory/Consultancy: Leuko; Advisory/Consultancy: Bioasis; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Eisai; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Samsung Bioepis; Research grant/Funding (institution): Ariad Pharmaceuticals; Research grant/Funding (institution): Baxalta GMBH/Servier Affaires; Research grant/Funding (institution): Bayer Healthcare; Research grant/Funding (institution): Guardant Health; Research grant/Funding (institution): Piqur Therapeutics; Research grant/Funding (institution): Puma C; Shareholder/Stockholder/Stock options: MedSIR; Research grant/Funding (institution): Queen Mary University of London. C. Seiberling: Travel/Accommodation/Expenses: Teva. B. Ataseven: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Tesaro; Honoraria (self): Celgene; Honoraria (self): Clovis; Honoraria (self): AstraZeneca; Travel/Accommodation/Expenses: PharmaMar. M. Dyson: Advisory/Consultancy: Merck; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Novartis; Advisory/Consultancy: EUSA Pharma; Advisory/Consultancy: AbbVie; Advisory/Consultancy: Janssen; Advisory/Consultancy: Biogen; Advisory/Consultancy: Menarini; Advisory/Consultancy: Norgine. O. Gluz: Advisory/Consultancy, Travel/Accommodation/Expenses: Celgene; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Genomic Health; Advisory/Consultancy: Amgen; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis; Advisory/Consultancy: Lilly; Advisory/Consultancy: Nanostring; Advisory/Consultancy: Eisai; Advisory/Consultancy: MSD; Travel/Accommodation/Expenses: Daiichi Sankyo. M. Reinisch: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: AstraZeneca; Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.